Prospective Study
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2015; 7(11): 361-368
Published online Nov 15, 2015. doi: 10.4251/wjgo.v7.i11.361
Tumor neoangiogenesis detection by confocal laser endomicroscopy and anti-CD105 antibody: Pilot study
Adriana Ciocâlteu, Adrian Săftoiu, Daniel Pirici, Claudia-Valentina Georgescu, Tatiana Cârţână, Dan Ionuț Gheonea, Lucian Gheorghe Gruionu, Cosmin Gabriel Cristea, Gabriel Gruionu
Adriana Ciocâlteu, Adrian Săftoiu, Tatiana Cârţână, Dan Ionuț Gheonea, Lucian Gheorghe Gruionu, Cosmin Gabriel Cristea, Gabriel Gruionu, Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
Daniel Pirici, Department of Research Methodology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
Claudia-Valentina Georgescu, Department of Pathology, Emergency County Hospital, 200642 Craiova, Romania
Lucian Gheorghe Gruionu, Department of Mechanical Engineering, University of Craiova, 200585 Craiova, Romania
Gabriel Gruionu, Edwin Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, United States
Author contributions: Ciocâlteu A, Săftoiu A and Gruionu G designed the research; Săftoiu A, Ciocâlteu A, Cârţână T and Gheonea DI performed the research; Pirici D, Gruionu LG and Georgescu CV contributed newreagents/analytic tools; Ciocâlteu A, Cristea CG, Pirici D and Georgescu CV analyzed the data; Ciocâlteu A wrote the paper; Săftoiu A, Gruionu G, Pirici D and Cristea CG revised and edited the paper.
Supported by National Research Council (CNCS), Romania, entitled ‘‘Clinical and Biomathematical Modeling of Vascular Changes Following Anti-Angiogenic Therapy in Advanced Colorectal Carcinoma’’, contract number PN-II-ID-PCE-2011-3-0664, and the European Social Found, Human Resources Development Operational Programme 2007- 2013, No. POSDRU/159/1.5/S/136893.
Institutional review board statement: The current study was conducted according to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004) and approved by the local Ethics Committee (No. 71/29.05.2014).
Clinical trial registration statement: Not applicable.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors have no competing interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Adrian Săftoiu, MD, PhD, MSc, FASGE, Professor, Research Center of Gastroenterology and Hepatology Craiova, University of Medicine and Pharmacy Craiova, Romania, 2 Petru Rares str., Craiova, Dolj 200349, Romania.
Telephone: +40-744-823355 Fax: +40-251-310287
Received: April 3, 2015
Peer-review started: April 4, 2015
First decision: May 18, 2015
Revised: June 9, 2015
Accepted: August 25, 2015
Article in press: September 7, 2015
Published online: November 15, 2015
Core Tip

Core tip: We evaluated CD105 expression from fresh tissue samples of human rectal adenocarcinoma, using confocal laser endomicroscopy (CLE). While vessels marked with fluorescent CD31 were visible in both normal and malignant tissue, CD105 was predominantly expressed in tumor lesions, having reduced affinity for normal rectal mucosa. Our data showed that CLE using CD105 antibody for tumor vascular network imaging is feasible and that CD105 represents a more specific marker for rectal cancer neoangiogenesis than panendothelial markers. To our knowledge, this is the first study to report the use of fluorescently-labeled CD105 antibody in conjunction with CLE in patients with rectal tumor.